Henrijette Richter
Direktor/Vorstandsmitglied bei Asceneuron SA
Ursprung des Netzwerks ersten Grades von Henrijette Richter
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
Sofinnova Partners SAS
 Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.
48
| Private Company | Investment Managers | 48 |
| Public Company | Financial Conglomerates | 21 | |
Asceneuron SA
 Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland.
12
| Holding Company | Pharmaceuticals: Major | 12 |
Comet Therapeutics, Inc.
 Comet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Comet Therapeutics, Inc. develops and commercializes treatments for patients suffering from metabolic, neurological and immunological disorders. The company was founded by Angellina Sekirnik and Enej Kuscer in 2008 and is headquartered in Cambridge, MA.
10
| Subsidiary | Pharmaceuticals: Major | 10 |
Mozart Therapeutics, Inc.
 Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning.
10
| Holding Company | Biotechnology | 10 |
Muna Therapeutics ApS
 Muna Therapeutics ApS Medical/Nursing ServicesHealth Services Muna Therapeutics ApS is a Danish private biopharmaceutical company that discovers and develops therapies to slow or stop neurodegenerative diseases such as Alzheimer's, frontotemporal dementia, and Parkinson's. Muna Therapeutics is based in Copenhagen, DK and was founded in 2020 by Simon Glerup and Bart de Strooper. The company focuses on identifying new medicines to preserve cognition and other brain functions and enhance resilience to these diseases. Rita Balice-Gordon has been the CEO of the company since 2020.
10
| Holding Company | Medical/Nursing Services | 10 |
NodThera Ltd.
 NodThera Ltd. BiotechnologyHealth Technology NodThera Ltd. researches and develops novel inhibitors of the NLRP3 inflammasome. The company is headquartered in Little Chesterford, the United Kingdom.
9
| Holding Company | Biotechnology | 9 |
iOmx Therapeutics AG
 iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany.
8
| Holding Company | Biotechnology | 8 |
Redona Therapeutics, Inc.
 Redona Therapeutics, Inc. BiotechnologyHealth Technology Redona Therapeutics, Inc.operates as a biotechnology company focused on the modulation of non- RNA (ncRNA) function to treat cancer and other human diseases. It uses small molecules to modulate expression levels of oncogenes and other proteins of significance in disease. The company was founded by George Daley, Richard Gregory, Frank Slack, and Piotr Sliz and is headquartered in Watertown, MA.
7
| Holding Company | Biotechnology | 7 |
Nitrase Therapeutics, Inc.
 Nitrase Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nitrase Therapeutics, Inc. develops drugs against newly discovered nitration enzyme. The firm provides disease modifying drugs for multiple additional aging-dependent diseases, such as neurodegenerative disease, heart disease and cancer. The company was founded by Irene Griswold-Prenner and is headquartered in Jackson, WY.
6
| Holding Company | Miscellaneous Commercial Services | 6 |
Novo Seeds
 Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark.
4
| Operating Division | Investment Managers | 4 |
Delinea, Inc. (United States)
 Delinea, Inc. (United States) BiotechnologyHealth Technology Delinia, Inc. operates as a biotechnology company that develops novel therapeutics for the treatment of autoimmune diseases. Its main program is a molecule that potentiates and expands Regulatory T Cells, powerful immune cells that are critical to maintaining self-tolerance and immune system homeostasis. Tregs are critically important immune regulatory cells in the path physiology of cancer and autoimmune disease. Delinia was founded by Michael Rosenblum and Jeffrey Greve in 2015 and is headquartered in Summit, NJ.
2
| Subsidiary | Biotechnology | 2 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Henrijette Richter
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| ORPHAZYME A/S | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member Chief Executive Officer Director/Board Member | |
| ABLYNX | Biotechnology | Director/Board Member Chairman Director/Board Member Director/Board Member | |
| Karolinska Institutet | College/University | Corporate Officer/Principal Corporate Officer/Principal Doctorate Degree Corporate Officer/Principal | |
Moon Surgical SAS
 Moon Surgical SAS Medical SpecialtiesHealth Technology Moon Surgical SAS is a French medical technology company that is creating a new category of robotic surgery. The company is based in Paris, France and is operated by renowned serial medical innovators and backed by leading venture capitalists. Its Maestro system enhances existing laparoscopic techniques and tools with new capabilities, benefiting the 93%% of patients who currently do not have access to minimally invasive robotic surgery. The CEO of the company is Anne Osdoit. | Medical Specialties | Director/Board Member Director/Board Member Chief Executive Officer Chief Operating Officer | |
May Health SAS
 May Health SAS Miscellaneous Commercial ServicesCommercial Services May Health SAS engages in the development of device for the treatment of polycystic ovary syndrome infertility. The company was founded in September 2017 and is headquartered in Paris, France. | Miscellaneous Commercial Services | Chairman Chairman Director/Board Member President | |
Wellington Partners GmbH
 Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor Private Equity Investor | |
Karolinska Development AB (Private Equity)
 Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Investment Managers | Chairman Chief Executive Officer Chief Executive Officer Chief Executive Officer | |
Forendo Pharma Oy
 Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member Director/Board Member | |
Galecto Biotech ApS
 Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member Corporate Officer/Principal | |
Akinion Pharmaceuticals AB
 Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chairman | |
| Ludwig-Maximilians-Universität München | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
MD Start SA
 MD Start SA BiotechnologyHealth Technology MD Start SA develops medical device technology. It has collaboration between venture capital, institutional investors and industry to the development of innovative medtech ideas in Europe. The company was founded by Tim Lenihanin 2010 and is headquartered in Paris, France. | Biotechnology | Chairman Director/Board Member Chief Investment Officer | |
| Technical University of Denmark | College/University | Graduate Degree Corporate Officer/Principal Graduate Degree | |
| Stanford University | College/University | Masters Business Admin Undergraduate Degree Doctorate Degree | |
| GALECTO, INC. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
SR One Capital Management LP
 SR One Capital Management LP Investment ManagersFinance SR One Capital Management LP (SR One) is a venture capital firm founded in 2020. The firm is headquartered in Redwood, California. | Investment Managers | Consultant / Advisor Corporate Officer/Principal Private Equity Investor | |
Tenpoint Therapeutics Ltd.
 Tenpoint Therapeutics Ltd. BiotechnologyHealth Technology Tenpoint Therapeutics Ltd. is a British biotechnology company that specializes in developing engineered cell-based therapies and in vivo reprogramming to restore vision for individuals with degenerative ocular diseases. The company is based in Cambridge, UK and was founded in 2020. Tenpoint Therapeutics brings together experts who are shaping the regenerative ocular medicine revolution and the technologies that are driving it. The company's focus is on replacing diseased cells with healthy ones to permanently restore vision. Eddy Anglade has been the CEO of the company since 2023. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| University of Cambridge | College/University | Doctorate Degree Masters Business Admin Doctorate Degree | |
| ROCHE HOLDING AG | Pharmaceuticals: Major | Sales & Marketing Corporate Officer/Principal Corporate Officer/Principal | |
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Corporate Officer/Principal | |
SafeHeal SAS
 SafeHeal SAS Medical SpecialtiesHealth Technology SafeHeal SAS develops anastomosis protection devices for improved patient recovery and reduced healthcare costs. The company is headquartered in Paris, France. | Medical Specialties | Chairman Director/Board Member President | |
HighLife SAS
 HighLife SAS Medical SpecialtiesHealth Technology HighLife SAS develops percutaneous mitral valve replacement therapies. It offers a minimally invasive prosthetic mitral valve that is implanted on a beating heart, while preserving the native valve structure and respecting the surrounding anatomy. The company was founded by Georg Börtle in 2010 and is headquartered in Paris, France. | Medical Specialties | Chief Tech/Sci/R&D Officer Director/Board Member Director/Board Member | |
| University of London | College/University | Corporate Officer/Principal Doctorate Degree Doctorate Degree | |
Modus Therapeutics AB
 Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chairman | |
| University College London | College/University | Undergraduate Degree Doctorate Degree Doctorate Degree | |
Delinea, Inc.
 Delinea, Inc. Information Technology ServicesTechnology Services Delinea, Inc. is a provider of privileged access management solutions for modern, hybrid enterprises. The private company is located in the US and has subsidiaries in Germany. The American company's platform extends PAM by providing authorization for all identities, granting access to an organization's most critical hybrid cloud infrastructure and sensitive data to help reduce risk, ensure compliance, and simplify security. Delinea serves customers worldwide, ranging from small businesses to the world's largest financial institutions, intelligence agencies, and critical infrastructure companies. | Information Technology Services | President Chief Executive Officer | |
Synthace Ltd.
 Synthace Ltd. Packaged SoftwareTechnology Services Synthace Ltd. produces bio-based chemical and biological products through synthetic biology. It is a synthetic biology company with a platform of technologies for the rapid engineering and optimization of novel biological production systems. The bioengineering platform is broadly applicable across multiple industry sectors, including the production of specialty chemicals from renewable feed stocks using efficient and sustainable processes. The company was founded by Sean Ward and Markus Christian Gershater in January 2011 and is headquartered in, London, the United Kingdom. | Packaged Software | Director/Board Member Director/Board Member | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
DNA Script SAS
 DNA Script SAS Medical SpecialtiesHealth Technology DNA Script engages in the provision of research and development in biotechnology. It manufactures synthetic deoxyribonucleic acid using enzymatic technology. The company was founded by Thomas Ybert, Sylvain Gariel and Xavier Godron in 2014 and is headquartered in Paris, France. | Medical Specialties | Director/Board Member Director/Board Member | |
| ABIONYX PHARMA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
Comet Biorefining, Inc.
 Comet Biorefining, Inc. BiotechnologyHealth Technology Comet Biorefining, Inc. operates as a holding company, which engages in the provision of cellulosic glucose technology for applications in renewable biofuels and biochemicals. It proprietary technology allows for the conversion of wood, wheat straw, bagasse, corn stover and other agricultural waste materials into high purity cellulosic glucose syrup. These non-food sources offer lower cost and price stability when compared to food sugar sources such as corn or sugar cane. The company was founded by Andrew Richard in 2009 and is headquartered in London, Canada. | Biotechnology | Director/Board Member Director/Board Member | |
The Column Group LLC
 The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Investment Managers | Private Equity Investor Private Equity Investor | |
| PIXIUM VISION | Medical Specialties | Director/Board Member Director/Board Member | |
Akamis Bio Ltd.
 Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member | |
| PLIANT THERAPEUTICS, INC. | Biotechnology | Chairman Director/Board Member | |
| University of Geneva | College/University | Graduate Degree Doctorate Degree | |
CorWave SA
 CorWave SA Medical SpecialtiesHealth Technology CorWave SA develops and manufactures blood pumps. The company was founded in 2011 and is headquartered in Paris, France. | Medical Specialties | Chairman Director/Board Member | |
| The University of Texas at Austin | College/University | Undergraduate Degree Doctorate Degree | |
Pcovery ApS
 Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Novo Holdings AS (Denmark)
 Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Financial Conglomerates | Corporate Officer/Principal Chief Investment Officer | |
Affinicon ApS
 Affinicon ApS Pharmaceuticals: MajorHealth Technology Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark. | Pharmaceuticals: Major | Chairman Director/Board Member | |
EpiTherapeutics ApS
 EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Director/Board Member Director/Board Member | |
| REDX PHARMA PLC | Pharmaceuticals: Major | Director/Board Member Director/Board Member |
Statistik
International
| Frankreich | 10 |
| Dänemark | 9 |
| Vereinigte Staaten | 9 |
| Vereinigtes Königreich | 8 |
| Schweden | 6 |
Sektoral
| Health Technology | 34 |
| Consumer Services | 10 |
| Finance | 6 |
| Technology Services | 3 |
| Commercial Services | 2 |
Operativ
| Director/Board Member | 690 |
| Corporate Officer/Principal | 177 |
| Chairman | 157 |
| Independent Dir/Board Member | 100 |
| Private Equity Investor | 86 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Steven Gillis | 58 |
| Gunnar Magnus Modee Persson | 51 |
| Antoine Papiernik | 48 |
| Viktor Drvota | 41 |
| Perry Karsen | 38 |
| Joshua Makower | 37 |
| Bo Jesper Hansen | 34 |
| Gerald Heinz Möller | 29 |
| Catherine Moukheibir | 29 |
| Nanna Liebach Lüneborg | 29 |
| Stephan Christgau | 29 |
| Deborah Harland | 27 |
| Denis Lucquin | 26 |
| Maina Bhaman | 26 |
| Graziano Seghezzi | 26 |
- Börse
- Insiders
- Henrijette Richter
- Unternehmensverbindungen
